Author: Marietta, Marco; Coluccio, Valeria; Luppi, Mario
Title: COVID-19, coagulopathy and venous thromboembolism: more questions than answers Cord-id: j3v3i8vm Document date: 2020_7_11
ID: j3v3i8vm
Snippet: The acute respiratory illnesses caused by severe acquired respiratory syndrome corona Virus-2 (SARS-CoV-2) is a global health emergency, involving more than 8.6 million people worldwide with more than 450,000 deaths. Among the clinical manifestations of COVID-19, the disease that results from SARS-CoV-2 infection in humans, a prominent feature is a pro-thrombotic derangement of the hemostatic system, possibly representing a peculiar clinicopathologic manifestation of viral sepsis. The severity o
Document: The acute respiratory illnesses caused by severe acquired respiratory syndrome corona Virus-2 (SARS-CoV-2) is a global health emergency, involving more than 8.6 million people worldwide with more than 450,000 deaths. Among the clinical manifestations of COVID-19, the disease that results from SARS-CoV-2 infection in humans, a prominent feature is a pro-thrombotic derangement of the hemostatic system, possibly representing a peculiar clinicopathologic manifestation of viral sepsis. The severity of the derangement of coagulation parameters in COVID-19 patients has been associated with a poor prognosis, and the use of low molecular weight heparin (LMWH) at doses registered for prevention of venous thromboembolism (VTE) has been endorsed by the World Health Organization and by Several Scientific societies. However, some relevant issues on the relationships between COVID-19, coagulopathy and VTE have yet to be fully elucidated. This review is particularly focused on four clinical questions: What is the incidence of VTE in COVID-19 patients? How do we frame the COVID-19 associated coagulopathy? Which role, if any, do antiphospolipid antibodies have? How do we tackle COVID-19 coagulopathy? In the complex scenario of an overwhelming pandemic, most everyday clinical decisions have to be taken without delay, although not yet supported by a sound scientific evidence. This review discusses the most recent findings of basic and clinical research about the COVID-associated coagulopathy, to foster a more thorough knowledge of the mechanisms underlying this compelling disease.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and lmwh prophylactic: 1
- acute ards respiratory distress syndrome and lmwh prophylaxis: 1, 2
- acute ards respiratory distress syndrome and lmwh treatment: 1, 2, 3
- acute ards respiratory distress syndrome and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and low incidence: 1, 2, 3, 4, 5, 6
- acute ards respiratory distress syndrome and low intensity: 1
- acute ards respiratory distress syndrome and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute ards respiratory distress syndrome and lupus anticoagulant: 1
- acutely ill and lmwh low molecular weight heparin: 1, 2, 3
- acutely ill and lmwh standard dose: 1
- acutely ill and lmwh weight heparin: 1, 2, 3
- acutely ill and low incidence: 1
- acutely ill and low molecular lmwh weight heparin: 1, 2, 3
- acutely ill and low molecular weight heparin: 1, 2, 3, 4, 5
- acutely ill and lung disease: 1, 2
Co phrase search for related documents, hyperlinks ordered by date